TPST-3003 / Tempest Therap - LARVOL DELTA

Tempest’s parallel CAR architecture is being applied across multiple programs (GlobeNewswire) - "(i) TPST-3003, an allogeneic CD19/BCMA dual-targeting CAR-T therapy under development for rrMM; (ii) TPST-4003, an in vivo CD19/BCMA dual-targeting CAR-T therapy under development for systemic lupus erythematosus (SLE) and other immunology disorders. Tempest expects initial clinical data from both programs later this year and believes this platform approach may allow these therapies to ultimately benefit a larger number of patients."

Clinical data • Multiple Myeloma • Systemic Lupus Erythematosus

Strategic Priorities (GlobeNewswire) - "Amezalpat remains Phase 3-ready in first-line hepatocellular carcinoma ('HCC'), supported by global regulatory alignment and positive randomized Phase 2 data. Tempest plans to pursue business development discussions to advance pivotal development...Tempest plans to progress additional dual-targeting CAR-T programs that broaden the platform across modalities and indications, including: TPST-3003: an allogeneic dual-targeting CD19/BCMA CAR-T; TPST-2206: a dual-targeting CD70/CD70 CAR-T; TPST-3206: an allogeneic dual-targeting CD70/CD70 CAR-T."

New P3 trial • Pipeline update • Hematological Malignancies • Hepatocellular Cancer • Immunology • Lupus • Renal Cell Carcinoma

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 (GlobeNewswire) - "Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR⍺ Antagonist, Phase 3-ready) and TPST-1495 (Dual Ep2/4 Antagonist, Phase 2 start expected near term)...The Proposed Transaction will expand and further diversify Tempest’s existing clinical-stage pipeline, with the acquisition of the first clinical-stage CD19/BCMA parallel structured dual-CAR T specifically designed to target patients with extramedullary disease (EMD), which we are referring to as TPST-2003...Tempest plans to pursue business development discussions or an additional financing to advance the pivotal development of amezalpat (TPST-1120) in first-line liver cancer ('HCC')....Plan to continue the development of additional new preclinical and research-stage pipeline programs: TPST-2206: dual-targeting CD70/CD70 CAR-T for renal cell carcinoma; TPST-3003: allogeneic dual-targeting CD19/BCMA; TPST-3206: allogeneic dual-targeting CD70/CD70."

M&A • Genetic Disorders • Hepatocellular Cancer • Multiple Myeloma • Renal Cell Carcinoma • Systemic Lupus Erythematosus